News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lundbeck Inc. to Make $16 Million Investment in Proximagen Group plc.


9/29/2011 7:48:39 AM

Danish pharmaceutical group Lundbeck is to invest 10.3 million pounds ($16.1 million) in British peer Proximagen Group PLC as part of a strategic partnership, the companies said on Thursday. Entering the deal would allow the companies to jointly use their expertise in central nervous system (CNS) drug development, the companies said in a statement. "Proximagen has built an exciting pipeline which offers real promise in treating a number of CNS disorders," Lundbeck's head of research and development, Anders Gersel Pedersen said in the statement.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES